Trial intelligence / Profile preview

Oral dabigatran penetration into vitreous and subretinal fluid in retinal detachment surgery

NL-OMON40980Active, not recruiting

Sponsor
Het Oogziekenhuis Rotterdam
Start
Nov 2014
Modality
Small Molecules
Countries
1
01

Overview

Open-label trial of dabigatran in rhegmatogenous retinal detachment (RRD) (3 arms), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoints: Dabigatran levels in ocular fluid and plasma and Antithrombin activity in ocular fluid and plasma. Started Nov 2014; status: active, not recruiting.

02

Drugs

dabigatran
03

Conditions

rhegmatogenous retinal detachment (RRD)

Beyond the preview

Go deeper on NL-OMON40980.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON40980.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call